Clinical Trial Update: Phase I Trial of 225Ac-J591 in Patients With mCRPC [Phase 1]

View source ↗

Summary

Phase I trial evaluating Actinium-225 labeled J591 (225Ac-J591) in metastatic castration-resistant prostate cancer has completed enrollment and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• 225Ac-J591 (Actinium-225-labeled J591)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Prostate Cancer | Phase 1 | Status: COMPLETED | Results posted: 2022-12-06